Share |

Content about United Therapeutics Corporation

August 24, 2011

One of the largest and most profitable biotechnology companies in the Mid-Atlantic is trying to increase its revenue by developing an oral form of treatment for pulmonary arterial hypertension (PAH).

Silver Spring-based United Therapeutics Corporation (NASDAQ: UTHR) released its FREEDOM-C(2) Phase 3 clinical trial results today but the company announced that the study did not meet its primary endpoint.

July 28, 2011

United Therapeutics Corporation is on track to reach revenues of $750 Million by the end of the year.

Silver Spring based United Therapeutics Corporation(NASDAQ: UTHR) said its still on track to reach revenues of $750 Million by the end of the year. Revenues for the second quarter of 2011 amounted to $183.8 Million a significant increase from 2010 second quarter where revenues were $134.7 Million.

June 16, 2011

Despite recession, several Maryland Biotechs turn a profit

Biotechnology firms have been reported to be hard hit by the recent recession; struggling to stay afloat amid a dearth of venture capital funding and and lack of new drugs selling on the market. The Biotech industry is often pigeonholed as frail, cash strapped and high risk; spending years on research to develop drugs but often ending with failure and bankruptcy.

But in Maryland it's a different story. Several biotech firms have achieved profitability for their full fiscal year and some of them for the first time in the midst of a troubled U.S. economy.

July 28, 2015

Silver Spring, Md-based United Therapeutics Corporation (NASDAQ: UTHR) remained profitable and increased revenues in the second quarter of 2015 but despite the growth, the company fell short of exceeding key analyst estimates .

March 17, 2015

Silver Spring, Maryland-based United Therapeutics Corporation (NASDAQ: UTHR) was the top gainer on Monday March 16, 2015, according to data from Google Finance biotechnology index. The fast growing company gained over $13 or 8.14% in a one-day trading session.

The stock price was already trading well over $170 for several days and has more than doubled from its 52-week low of $84.63.

March 21, 2014

Washington, D.C.-based Vanda Pharmaceuticals Inc (NASDAQ:VNDA), has launched a couple of drugs and even recently put into place a television ad campaign. The company is now in need of extra space and will expand into an additional 8,600 square feet at its D.C. headquarters located at 2200 Pennsylvania Avenue.

Vanda will pay the landlord, Square 54 Office Owner LLC, and additional $381,000 for a 12 year and one month term lease beginning on September 1, 2014, although Vanda will get a nine month grace period.

March 13, 2014

In late 2012 Sucampo Pharmaceuticals (NASDAQ: SCMP) received approval from the Food and Drug Administration (FDA)  to expand upon its gastrointestinal drug -- AMITIZA -- to treat people with opioid-induced constipation (OIC) in the United States.

With increasing competition from other biotechnology companies, that approval is keeping the Bethesda-based drug developer ahead of them and profitable, with a net income posted in 3 out of the last 4 quarters of 2013, including the most recent fourth quarter.

March 13, 2014

Germantown, Maryland-based Intrexon Corporation (NYSE:XON) stock was recently upgraded by EVA Dimensions last week but that doesn’t explain yesterdays price surge of more than 10 percent for the company.

Intrexon was the third most price-trending stock on Google Finance yesterday, the stock price of the company increased more than 11.46 percent (+ $3.14) to close at $30.55 per share.

A few reasons that could have driven Intrexon’s stock price higher,

March 13, 2014

In late 2012 Sucampo Pharmaceuticals (NASDAQ: SCMP) received approval from the Food and Drug Administration (FDA)  to expand upon its gastrointestinal drug -- AMITIZA -- to treat people with opioid-induced constipation (OIC) in the United States.

With increasing competition from other biotechnology companies, that approval is keeping the Bethesda-based drug developer ahead of them and profitable, with a net income posted in 3 out of the last 4 quarters of 2013, including the most recent fourth quarter.

February 28, 2014

Silver Spring, Maryland-based United Therapeutics Corporation (NASDAQ:UTHR) crossed well over $1 billion in revenue for the first time in its corporate history and according to CEO Martine Rothblatt J.D., Ph.D., 2014 will be an even better year.

February 6, 2012

United Therapeutics Corporation (NASDAQ: UTHR)said it received notice from a generic drug manufacturer that it intends to release a remanufactured form of one of Silver Spring-based company's core drugs called Remodulin.

Sandoz Inc, submitted a Paragraph IV Certification Notice Letter which United Therapeutics received on February 3, 2012. The letter states that the company has sent an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) also in Silver Spring.

December 27, 2011

The D.C. areas largest biotech gets drug approval in Europe

Silver Spring-based United Therapeutics Corporation (NASDAQ: UTHR) continues to expand into new markets with the French regulatory agency approval of the Intravenous form of its Pulmonary Arterial Hypertension drug Remodulin.

October 27, 2011

The largest independent biotechnology company in the Baltimore-Washington area far exceed analyst expectations

Silver Spring-based United Therapeutics Corporation (NASDAQ: UTHR), the largest independent biotechnology company in the Baltimore-Washington area measured by market value, announced financial results today that far exceeded  analyst estimates.

In the third quarter ended September 30, 2011, United Therapeutics reported total revenues of $201.7 million, a year-over-year increase of 20 percent from $168.6 million. Revenues beat the average analyst estimate of $194.77 million.